Indication

In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

Medicine details

Medicine name:
pertuzumab (Perjeta)
SMC ID:
SMC2284
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC